Immunotherapy Combinations Have Mechanistic Rationale in Ovarian Cancer – Targeted Oncology
Targeted Oncology |
Immunotherapy Combinations Have Mechanistic Rationale in Ovarian Cancer
Targeted Oncology Differential PI3Kδ signaling in CD4+ T cell subsets enables selective targeting of T regulatory cells to enhance cancer immunotherapy. Canc Res. 2017;77(8):1892-1904. doi: 10.1158/0008-5472.CAN-16-1839. Higuchi T, Flies DB, Marion NA, et al. CTLA-4 … |
|
Novel approach may prolong remission after T-cell immunotherapy for leukemia, lymphoma
Healio Researchers at Seattle Children’s Hospital have launched a first-in-human trial to investigate whether infusions of T-cell antigen–presenting cells prolong the persistence of chimeric antigen receptor T-cell immunotherapy among children with relapsed … |